4-(6-methoxyquinolin-2-yl)-N-methylaniline | 1246092-15-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 4-(6-methoxyquinolin-2-yl)-N-methylaniline
• CAS: 1246092-15-8
• 化学式: C₁₇H₁₆N₂O
• 分子量: 264.327
• InChiKey: OGRQGWZRIZAYIC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  20
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  34.2
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  4-(N-甲基氨基)苯硼酸频那醇酯 、 2-氯-6-甲氧基喹啉 以51%的产率得到4-(6-methoxyquinolin-2-yl)-N-methylaniline
  参考文献：
  名称：

  Imaging agents for detecting neurological disorders

  摘要：

  本文提供了一种公式（I）的成像剂和检测神经系统疾病的方法，包括向需要的患者施用能够结合tau蛋白和β-淀粉样肽的公式（I）化合物。该发明还涉及成像Aβ和tau聚集物的方法，包括引入含有公式（I）放射标记化合物的制剂的可检测量，并检测与淀粉样沉积物和/或tau蛋白相关的标记化合物在患者体内的情况。这些方法和组合物使得能够进行临床前诊断和监测阿尔茨海默病和其他神经系统疾病的进展。

  公开号：

  US20100239496A1

文献信息

• Imaging Agents for Detecting Neurological Disorders
  申请人：Szardenings Anna Katrin

  公开号：US20110182812A1

  公开（公告）日：2011-07-28

  Imaging agents of formulas (I)-(V) and methods for detecting neurological disorders comprising administering to a patient in need compounds of formulas (I)-(V) capable of binding to tau proteins and β-amyloid peptides are presented herein. The invention also relates to methods of imaging Aβ and tau aggregates comprising introducing a detectable quantity of pharmaceutical formulation comprising a radiolabeled compound of formulas (I)-(V) and detecting the labeled compound associated with amyloid deposits and/or tau proteins in a patient. These methods and compositions enable preclinical diagnosis and monitoring progression of AD and other neurological disorders.

  本文介绍了公式（I）-（V）的成像剂和用于检测神经系统疾病的方法，其中包括向需要治疗的患者注射能够结合tau蛋白和β-淀粉样肽的公式（I）-（V）化合物。本发明还涉及成像Aβ和tau聚集物的方法，包括引入含有放射性标记的公式（I）-（V）化合物的制剂，并检测与淀粉样沉积物和/或tau蛋白相关联的标记化合物。这些方法和组合物可用于预临床诊断和监测AD和其他神经系统疾病的进展。
• IMAGING AGENTS FOR DETECTING NEUROLOGICAL DISORDERS
  申请人：Siemens Medical Solutions USA, Inc.

  公开号：EP2411057A2

  公开（公告）日：2012-02-01
• US8491869B2
  申请人：——

  公开号：US8491869B2

  公开（公告）日：2013-07-23
• [EN] IMAGING AGENTS FOR DETECTING NEUROLOGICAL DISORDERS<br/>[FR] AGENTS D'IMAGERIE POUR DÉTECTER DES TROUBLES NEUROLOGIQUES
  申请人：SIEMENS MEDICAL SOLUTIONS

  公开号：WO2010111303A2

  公开（公告）日：2010-09-30

  Imaging agents of formula (I) and methods for detecting neurological disorders comprising administering ti a patient in need compounds of formula (I) capable of binding to tau proteins and β-amyloid peptides are presented herein. The invention also relates to methods of imaging Aβ and tau aggregates comprising introducing a detectable quantity of pharmaceutical formulation comprising a radiolabeled compound of formula (I) and detecting the labeled compound associated with amyloid deposits and/or tau proteins in a patient. These methods and compositions enable preclinical diagnosis and monitoring progression of AD and other neurological disoders.
• [EN] SARS-C0V-2 INACTIVATION BY ETHACRIDINE<br/>[FR] INACTIVATION DE SARS-COV-2 PAR L'ÉTHACRIDINE
  申请人：[en]THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

  公开号：WO2022093871A1

  公开（公告）日：2022-05-05

  Herein, existing and approved drugs that were not previously used as antiviral agents are disclosed that may be readily repurposed to treat viral infections, including COVID-19. In a primary implementation, ethacridine and derivatives thereof are utilized in methods of treating viral infections, including COVID-19. Drug delivery devices for administering ethacridine are provided. Also disclosed are novel reporters of SARS-CoV-2 Mpro activity that may be utilized to identify novel agents for treating viral infections such as COVID-19.